Trial Profile
A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate (DIALIZE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- Acronyms DIALIZE
- Sponsors AstraZeneca
- 24 Nov 2020 According to an AstraZeneca media release, based on the data from this study National Medical Products Administration (NMPA) has approved a dosing label update in China for Lokelma (sodium zirconium cyclosilicate) to include patients with hyperkalaemia on chronic haemodialysis.
- 20 Oct 2020 According to an AstraZeneca media release, new sub-analyses of this Phase IIIb trial will be presented at the at ASN Kidney Week 2020 Reimagined, taking place virtually from 22th-25th Oct 2020.
- 05 Jun 2020 According to an AstraZeneca media release, ERA-EDTA 2020 Virtual Congress abstracts will be made available online on Friday 5 June 2020 in an abstract supplement to be published with the June issue of the Nephrology Dialysis Transplantation Journal